Envisagenics Secures Series B Funding to Advance AI-Driven RNA Splicing Therapeutics
Envisagenics is a revenue-generating biotechnology company that leverages AI to accelerate the discovery of therapeutic targets and drugs.
Company Name: Envisagenics
Location: NYC, NY
Sector: Biotechnology, Artificial Intelligence
Funding Details: Raised an undisclosed amount in Series B funding. The round included existing investors Third Kind Venture Capital, Empire State Development, and Red Cell Partners, as well as new strategic investor Bristol Myers Squibb (NYSE: BMY), which also collaborates with Envisagenics in oncology research.
Purpose of Investment: To further develop its preclinical oncology asset pipeline and scale commercial offerings using its cloud-based AI drug discovery platform, SpliceCore®.
Leadership: Founded by Maria Luisa Pineda, Ph.D., co-founder and CEO, as a spin-out from Cold Spring Harbor Laboratory.
Product: Envisagenics focuses on the discovery and development of novel RNA splicing therapeutics using its SpliceCore® platform. This platform integrates machine learning algorithms with high-performance computing to analyze an extensive proprietary database of over 14 million RNA splicing events, identifying novel and disease-specific alternative splicing isoforms.
About Company: Envisagenics is a revenue-generating biotechnology company that leverages AI to accelerate the discovery of therapeutic targets and drugs. The company’s AI-driven approach aims to revolutionize how novel therapeutics are discovered and developed in the biotechnology sector, particularly in oncology.